Agonist of stimulator of interferon genes as antitumor agents: a patent review (2008-2020)

References

• Ishikawa H, Barber GN. STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. Nature. 2008;455(7213):674–U74.
   PubMed Web of Science ®Google Scholar
• Danilchanka O, Mekalanos JJ. Cyclic dinucleotides and the innate immune response. Cell. 2013;154(5):962–970.
   PubMed Web of Science ®Google Scholar
• Shang G, Zhang C, Chen ZJ, et al. Cryo-EM structures of STING reveal its mechanism of activation by cyclic GMP–AMP. Nature. 2019;567(7748):389–393. .
   PubMed Web of Science ®Google Scholar
• Hopfner KP, Hornung V. Molecular mechanisms and cellular functions of cGAS-STING signalling. Nat Rev Mol Cell Biol. 2020;21(9):501–521.
   PubMed Web of Science ®Google Scholar
• Sun LJ, Wu JX, Du FH, et al. Cyclic GMP-AMP synthase is a cytosolic dna sensor that activates the type i interferon pathway. Science. 2013;339(6121):786–791. .
   PubMed Web of Science ®Google Scholar
• Margolis SR, Wilson SC, Vance RE. Evolutionary origins of cGAS-STING signaling. Trends Immunol. 2017;38(10):733–743.
   PubMed Web of Science ®Google Scholar
• Chin EN, Yu C, Vartabedian VF, et al. Antitumor activity of a systemic STING-activating non-nucleotide cGAMP mimetic. Science. 369(6506): 993–999. 2020; .
   PubMed Web of Science ®Google Scholar
• Dobbs N, Burnaevskiy N, Chen DD, et al. STING activation by translocation from the ER is associated with infection and autoinflammatory disease. Cell Host Microbe. 2015;18(2):157–168. .
   PubMed Web of Science ®Google Scholar
• Wu -JJ, Zhao L, Hu HG, et al. Agonists and inhibitors of the STING pathway: potential agents for immunotherapy. Med Res Rev. 2020;40(3):1117–1141. .
   PubMed Web of Science ®Google Scholar
• Ergun SL, Fernandez D, Weiss TM, et al. STING polymer structure reveals mechanisms for activation, hyperactivation, and inhibition. Cell. 2019;178(2):290–301 e10. .
   PubMed Web of Science ®Google Scholar
• Cui X, Zhang R, Cen S, et al. STING modulators: predictive significance in drug discovery. Eur J Med Chem. 2019;182:111591.
   PubMed Web of Science ®Google Scholar
• Yang H, Lee WS, Kong SJ, et al. STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade. J Clin Investig. 2019;129(10):4350–4364.
   PubMed Web of Science ®Google Scholar
• Su T, Zhang Y, Valerie K, et al. STING activation in cancer immunotherapy. Theranostics. 2019;9(25):7759–7771.
   PubMed Web of Science ®Google Scholar
• Diner EJ, Burdette DL, Wilson SC, et al. The innate immune DNA Sensor cGAS produces a noncanonical cyclic dinucleotide that activates human STING. Cell Rep. 2013;3(5):1355–1361. .
   PubMed Web of Science ®Google Scholar
• Du XX, Su XD. Detection of cyclic dinucleotides by STING. Methods Mol Biol. 2017;1657:59–69.
   PubMedGoogle Scholar
• Che X, Zhang J, Quan H, et al. CDNs–STING interaction mechanism investigations and instructions on design of CDN-derivatives. J Phys Chem A. 2018;122(6):1862–1868.
   Web of Science ®Google Scholar
• Feng X, Liu DY, Li ZY, et al. Bioactive modulators targeting STING adaptor in cGAS-STING pathway. Drug Discov Today. 25(1): 230–237. 2020; .
   PubMed Web of Science ®Google Scholar
• Corrales L, Glickman LH, McWhirter SM, et al. Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity. Cell Rep. 2015;11(7):1018–1030.
   PubMed Web of Science ®Google Scholar
• Berger G, Marloye M, Lawler SE. Pharmacological modulation of the sTING pathway for cancer immunotherapy. Trends Mol Med. 2019;25(5):412–427. .0
   PubMed Web of Science ®Google Scholar
• Altman MD, Cash BD, Chang W, et al. Benzo [b] thiophene compounds as STING agonists. WO. 2018;2018067423:A1.
   Google Scholar
• Ramanjulu JM, Pesiridis GS, Yang J, et al. Design of amidobenzimidazole STING receptor agonists with systemic activity. Nature. 564(7736): 439–443. 2018; .0
   PubMed Web of Science ®Google Scholar
• Zhang H, You QD, Xu XL. Targeting stimulator of interferon genes (STING): a medicinal chemistry perspective. J Med Chem. 2020;63(8):3785–3816.
   PubMed Web of Science ®Google Scholar
• Che X, Zhang J, Zhu Y, et al. Structural flexibility and conformation features of cyclic dinucleotides in Aqueous Solutions. J Phys Chem B. 2016;120(10):2670–2680. .
   PubMed Web of Science ®Google Scholar
• Li L, Yin Q, Kuss P, et al. Hydrolysis of 2ʹ3’-cGAMP by ENPP1 and design of nonhydrolyzable analogs. Nat Chem Biol. 2014;10(12):1043–1048.
   PubMed Web of Science ®Google Scholar
• Katiban GE, Kanne D, Sung L, et al. Methods for identifying inhibitors of “stimulator of interferon gene”-dependent interferon production. WO. 2017;2017106740:A1.
   Google Scholar
• Zhong B, Sun L, Wei Q, et al. Cyclic di-nucleotide compounds and methods of use. WO. 2017;2017161349:A1.
   Google Scholar
• Wu WL, Lim J, Cumming JN, et al. Cyclic di-nucleotide compounds as STING agonists. WO. 2018;2018208667:A1.
   Google Scholar
• Emanuel S, Richter M, Connolly P, et al. Cyclic dinucleotides as STING agonists. WO. 2018;2018138685:A2.
   Google Scholar
• Beigenlman L, Bignan G, Connolly P, et al. Cyclic dinucleotides as STING agonists. WO. 2019;2019118839:A1.
   Google Scholar
• Glick G, Ghosh S, Roush W, et al. Cyclic dinucleotide analogs for treating conditions associated with STING (stimulator of interferon genes) activity. WO. 2018;2018045204:A1.
   Google Scholar
• Iyer RP, Meher G, Sheri A, et al. Compounds compositions, and methods for the. WO. 2019;2019051488:A1.
   Google Scholar
• Iyer RP, Challa S, Zhou S. Nanoparticle formulations of STING agonists related applications. WO. 2019;2019161171:A1.
   Google Scholar
• Xi Z, Wang ZH, Wang D. Cyclic dinucleotide prodrug molecule, preparation method therefor and application thereof. WO. 2020;2020143740:A1.
   Google Scholar
• Birkus G, Pav O, Rosenberg I, et al. 2ʹ2’ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein. US. 2019;2019185509:A1.
   Google Scholar
• Birkus G, Pav O, Rosenberg I, et al. 2ʹ2’ cyclic dinucleotides. WO. 2019;2019193542:A1.
   Google Scholar
• Adams JL, Duffy KJ, Lian YQ. Cyclic purine dinucleotides as modulators of sting. WO. 2017;2017093933:A1.
   Google Scholar
• Altman MD, Andresen B, Chang W, et al. Cyclic purine dinucleotides as modulators of sting. WO. 2017;2017027645:A1.
   Google Scholar
• Curran MA, Di Francedco M, Jones P. Cyclic dinucleotides as agonists of stimulator of interferon gene dependent signalling. WO. 2018;2018156625:A1.
   Google Scholar
• Bignan GC, Connolly P, Edwards JP, et al. Cyclic dinucleotides as sting agonists. WO. 2018;2018098203:A1.
   Google Scholar
• Katibah GE, Kanne D, Sung L, et al. Compositions and methods for activating “stimulator of interferon gene”-dependent signalling. WO. 2017;2017075477:A1.
   Google Scholar
• Altman MD, Andresen B, Chang W, et al. Cyclic di-nucleotide compounds as sting agonists. WO. 2017;2017027646:A1.
   Google Scholar
• Fink BE, Dodd DS, Qin L, et al. Cyclic dinucleotides as anticancer agents. WO. 2019;2019023459:A1.
   Google Scholar
• Vyskocil S, Ciavarri J, Cullis C, et al. Sting modulator compounds, and methods of making and using. WO. 2019;2019092660:A1.
   Google Scholar
• Wu RG, Yi DW. Cyclic dinucleotide compound, preparation method and application thereof. 2019;CN109694397:A.
   Google Scholar
• Verenjoul F, Drocourt D, Romo J, et al. Combined use of a chemotherapeutic agent and a cyclic dinucleotide for cancer treatment. WO. 2016;2016096577:A1.
   Google Scholar
• Lioux T, Mauny MA, Lamoureux A, et al. Design, synthesis, and biological evaluation of novel cyclic adenosine-inosine monophosphate (cAIMP) analogs that activate stimulator of interferon genes (STING). J Med Chem. 2016;59(22):10253–10267. .
   PubMed Web of Science ®Google Scholar
• Wang C, Sinn M, Stifel J, et al. Sommershof A, Hartig JS. Synthesis of all possible canonical (3ʹ-5ʹ-Linked) cyclic dinucleotides and evaluation of riboswitch interactions and immune-stimulatory effects. J Am Chem Soc. 2017; 13945: 16154–16160.
   PubMed Web of Science ®Google Scholar
• Fink BE, Dodd DS, Qin L, et al. Cyclic dinucleotides as anticancer agents. WO. 2019;2019074887:A1.
   Google Scholar
• Kim DS, Fang F, Endo A, et al. Methods for the treatment of bladder cancer. WO. 2019;2019232392:A1.
   Google Scholar
• Genieser HG, Schwede F, Rentsch A. Cyclic dinucleotides containing benzimidazole, method for the production of same, and use of same to activate stimulator of interferon genes (sting)-dependent signaling pathways. WO. 2018;2018065360:A1.
   Google Scholar
• Harikrichnan LS, Kamau MG. Cyclic dinucleotides as anticancer agents. WO. 2019;2019046496:A1.
   Google Scholar
• Bonnac LF, Dreis CD, Geraghty RJ, et al. Structure activity relationship, 6-modified purine riboside analogues to activate hSTING, stimulator of interferon genes. Bioorg Med Chem Lett. 2020;30(2):2. .
   Web of Science ®Google Scholar
• Hospital AJ, Paget S, Kaelin DEJ, et al. Novel sting agonists. WO. 2020;2020092127:A1.
   Google Scholar
• Altman MD, Cash BD, Chang W, et al. Aza-benzothiophene compounds as sting agonists. WO. 2019;2019195063:A1.
   Google Scholar
• Abdel-Magid Ahmed Potential cancer treatment by agonists of the stimulator of interferon genes. ACS Med Chem Lett. 2020;11(6):1081–1082.
   PubMedGoogle Scholar
• Zhang A, Geng MY, Ding CY, et al. Fluorine-containing substituted benzothiophene compound, and pharmaceutical composition and application thereof. WO. 2020;2020140894:A1.
   Google Scholar
• Zhang A, Geng MY, Ding CY, et al. A class of benzothiophene compounds and their pharmaceutical compositions and applications. 2020;CN111393404:A.
   Google Scholar
• Altman MD, Cash BD, Chang W, et al. Benzothiophenes and related compounds as sting agonists. WO. 2019;2019195124:A1.
   Google Scholar
• Leit DM, Romero DL, Knight J, et al. Sting heterocycle agonists and uses thereof. WO. 2020;2020132549:A1.
   Google Scholar
• Charnley AK, Darcy MG, Dodson JW, et al. Heterocyclic amides useful as protein modulators. WO. 2017;2017175156:A1.
   Google Scholar
• Li GY, Tian Q, Niu XD, et al. Heterocyclic amide compound, pharmaceutical composition containing heterocyclic amide compound, preparation method of heterocyclic amide compound and application of heterocyclic amide compound. CN. 2020;110963997:A1.
   Google Scholar
• Li J, Zhang DY, Pan F, et al. Immunomodulator. WO. 2019;2019134707:A1.
   Google Scholar
• Li J, Zhang DY, Pan F, et al. Macrocyclic immunomodulator. WO. 2020;2020151682:A1.
   Google Scholar
• Cherry S, Sali TM, Pryke KM, et al. Characterization of a Novel Human-Specific STING Agonist that Elicits Antiviral Activity Against Emerging Alphaviruses. PLoS Pathog. 2015;11:12.
   Web of Science ®Google Scholar
• Chen YF, Chen KX, Li P, et al. High activity sting protein agonist. WO. 2020;2020038387:A1.
   Google Scholar
• Charnley AK, Darcy MG, Dodson JW, et al. Heterocyclic amides useful as protein modulators. WO. 2017;2017175147:A1.
   Google Scholar
• Li J, Zhang DY, Wei YG, et al. Immunomodulator. WO. 2019;2019134705:A1.
   Google Scholar
• Fosbenner DT, Graybill TL, Kang J, et al. Modulators of stimulator of interferon genes (sting). WO. 2019;2019069270:A1.
   Google Scholar
• Wu LX, Lajkiewicz N, Yao WQ. Heteroaryl amide compounds as sting activators. WO. 2020;2020028566:A1.
   Google Scholar
• Leit De Moradei SM, Romero DL, Knight J, et al. Sting agonists and uses thereof. 2020;WO2020132582:A1.
   Google Scholar
• Liu D, Chen L, Zhuang LH, et al. Fused tricyclic heterocycle compounds and therapeutic uses. WO. 2020;2020006432:A1.
   Google Scholar
• Liu D, Li PH, Zhuang LH, et al. Tricyclic compounds as sting agonists, and preparation methods. WO. 2020;2020124059:A1.
   Google Scholar
• Wu LX, Lajkiewicz N, Ye YD, et al. Tricyclic heterocyclic compounds as sting activators. WO. 2019;2019227007:A1.
   Google Scholar
• Wu LX, Lajkiewicz N, Yao WQ. Heteroaryl amide compounds as sting activators. WO. 2020;2020146237:A1.
   Google Scholar
• Banerjee M, Middya S, Basu S, et al. Heterocyclic small molecule modulators of human STING. WO. 2018;2018234807:A1.
   Google Scholar
• Banerjee M, Middya S, Basu S, et al. Small molecule modulators of human STING. WO. 2018;2018234805:A1.
   Google Scholar
• Banerjee M, Middya S, Basu S, et al. Small molecule modulators of human STING. WO. 2018;2018234808:A1.
   Google Scholar
• Banerjee M, Middya S, Basu S, et al. Azaheterocyclic small molecule modulators of human STING. WO. 2019;2019243823:A1.
   Google Scholar
• Laieson LL, Chin EN, Chatterjee A, et al. Agonists of stimulator of interferon genes STING. WO. 2019;2019165032:A1.
   Google Scholar
• Gajewski TF, Higgs EF. Immunotherapy with a sting. Science. 2020;369(6506):921–922.
   PubMed Web of Science ®Google Scholar
• Hanada R, Kokubo M, Kurono M, et al. STING-agonist compound. WO. 2020;2020075790:A1.
   Google Scholar
• Chang JH, Du YM, Guo JT. Benzamide derivatives as cGAS-STING pathway agonists. WO. 2020;2020072492:A1.
   Google Scholar
• Zhang X, Liu B, Tang L, et al. Discovery and Mechanistic Study of a Novel Human-Stimulator-of-Interferon-Genes Agonist. ACS Infect Dis. 2019;5(7):1139–1149.
   PubMed Web of Science ®Google Scholar
• Dobezanska MP, Zawadzka MI, Radzimierski A, et al. Modulators of stimulator of interferon genes (STING). WO. 2019;2019238786(A1).
   Google Scholar
• Pan BS, Perera SA, Piesvaux JA, et al. An orally available non-nucleotide STING agonist with antitumor activity. Science 2020; 369(6506):935–+.
   Google Scholar
• Gogoi H, Mansouri S, Jin L. The Age of Cyclic Dinucleotide Vaccine Adjuvants. Vaccines (Basel). 2020;8(3):3.
   Web of Science ®Google Scholar
• Gremel G, Impagnatiello MA, Carotta S, et al. Abstract 4522: Potent induction of a tumor-specific immune response by a cyclic dinucleotide STING agonist. 2020, 80 (16 Supplement), 4522-4522.
   Google Scholar
• Allen BK, Chamberlain BT, Jernigan FE, et al. Oxoacridinyl acetic acid derivatives and methods of use. WO. 2019;2019100061:A1.
   Google Scholar